<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To summarize the clinical features of invasive pulmonary <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> (IPFI) secondary to malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e> (MBD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We retrospectively analyzed the clinical data of 52 patients with IPFI secondary to MBD admitted to Peking Union Medical College Hospital from January 1995 to December 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The incidences of IPFI secondary to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) were 4.6%, 3.2%, 2.8%, and 2.5%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with IPFI secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 88.5% (23/26) of the patients suffered from the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> during the non-remission (NR) period (including relapse), and 11.5% (3/26) in the complete-remission (CR) period </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> the patients with IPFI secondary to malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e>, 86.5% (45/52) of MBD were neutropenic or agranulocytic, and 67.3% (35/52) had been treated with broad-spectrum antibiotics for more than 96 hours before anti-fungal therapy </plain></SENT>
<SENT sid="5" pm="."><plain>The total mortality after anti-fungal therapy was 13.7% (7/51) </plain></SENT>
<SENT sid="6" pm="."><plain>More than half of patients with <z:chebi fb="2" ids="46081">fluconazole</z:chebi> or <z:chebi fb="0" ids="6076">itraconazole</z:chebi> as the first-line therapy had to switch to other medicines because of poor <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> control </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: IPFI secondary to MBD is most common in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with NR of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> or <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, and long-term broad-spectrum antibiotics usage are susceptible to IPFI </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="2" ids="46081">Fluconazole</z:chebi> and <z:chebi fb="0" ids="6076">itraconazole</z:chebi> have low efficacy, and other more potent anti-fungal medicines should be considered </plain></SENT>
</text></document>